首页> 美国卫生研究院文献>Laboratory Animal Research >Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans
【2h】

Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans

机译:由海带和月见草提取物组成的FEMY-R7对小鼠和人的幽门螺杆菌活性的比较分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Helicobacter pylori-eliminating effects of FEMY-R7, composed of Laminaria japonica and Oenothera biennis extracts, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1×109 CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with total 20, 64 or 200 mg/kg/day FEMY-R7 for 2 weeks. In Campylobcter-like organism (CLO)-detection tests on gastric mucosa and feces, FEMY-R7 reduced the urease-positive reactivity in a dose-dependent manner; i.e., the positivity ratios were decreased to 70, 20, and 10% for gastric mocosa and to 80, 50, and 20% for feces. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with capsules containing total 100, 320 or 1,000 mg/man/day FEMY-R7 (matching doses for 20, 64 or 200 mg/kg/day, respectively, in mice from a body surface area-based dose translation) for 8 weeks. FEMY-R7 decreased the positivity ratios in feces to 70, 40, and 30%, respectively. In bacterial culture, H. pylori was identified from the CLO-positive stools of mice and humans. The bacterial identification ratios exhibited a good correlation between the matching doses in mice and humans. It is suggested that FEMY-R7 could be a promising functional food without tolerance as an adjunct to reduce the dosage of antibiotics for the treatment of recurrent H. pylori infection.
机译:在小鼠和人类中研究了由海带和月见草提取物组成的FEMY-R7消除幽门螺杆菌的作用。雄性C57BL / 6小鼠通过胃内接种(1×10 9 CFU /小鼠)每隔2天感染3次,并每天口服两次,共20、64次,被细菌感染或200 mg / kg / day FEMY-R7,持续2周。在对胃粘膜和粪便的弯曲杆菌样生物(CLO)检测试验中,FEMY-R7以剂量依赖的方式降低了脲酶阳性反应性。即,胃粘膜的阳性率降低到70%,20%和10%,粪便的阳性率降低到80%,50%和20%。在临床研究中,已确认已感染幽门螺杆菌的人类受试者每天口服两次,每次胶囊含100、320或1,000毫克/人/天的FEMY-R7(匹配剂量为20、64或200毫克/人/天kg /天,分别来自小鼠,基于体表面积的剂量转换),持续8周。 FEMY-R7将粪便中的阳性率分别降低至70%,40%和30%。在细菌培养中,从小鼠和人的CLO阳性粪便中鉴定出幽门螺杆菌。细菌识别率在小鼠和人类的匹配剂量之间显示出良好的相关性。有人建议,FEMY-R7可以作为一种有希望的功能食品而没有耐受性,可以作为减少治疗复发性幽门螺杆菌感染的抗生素的辅助剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号